Eli Lilly recently acquired a smaller biotech for its promising investigational pain medication. The company generates strong ...

The phase 4 study is known as IXORA-R. This study was a head to head study between Taltz and Tremfya. There were a total of 1,027 patients with moderate to severe plaque psoriasis. The primary ...

The minute-long commercial, featuring lots of bare shoulders, midriffs and swimsuits, promotes a new drug by Eli Lilly and Co. called Taltz that treats red, scaly patches of skin caused by ...

Eli Lilly courts physicians with blockbuster-topping Taltz data In the June data presentation, 36% of patients treated with Taltz hit both markers at 24 weeks, topping Humira, which saw only 28% ...

INDIANAPOLIS, Aug. 13, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today Taltz ® (ixekizumab) met the primary and all major secondary endpoints up to week 12 in the Phase 4 ...

Eli Lilly and Company’s LLY shares have lost 17% so far in May. Lilly announced mixed earnings results on May 1. It missed first-quarter estimates for earnings but beat the same for sales. Sales of ...

Eli Lilly announced that the Food and Drug Administration (FDA) has approved Taltz (ixekizumab) injection for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for ...

Eli Lilly's Taltz and Novartis' Cosentyx have been jockeying for IL-17 inhibitor supremacy with back-and-forth FDA approvals for years. But in the race for a fourth indication, Taltz has come out ...

INDIANAPOLIS, May 22, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz ® (ixekizumab ...

That showed Taltz was able to work well and achieve the primary goal in both studies. The first late-stage study, known as COAST-V, evaluated patients who didn't take any antirheumatic drug ...

Drugmaker Eli Lilly & Co (LLY) said that the U.S. Food and Drug Administration (FDA) has approved a supplemental Biologics License Application (BLA) for its Taltz injection used for the treatment ...

The SPIRIT-H2H trial is the first completed large head-to-head or H2H superiority study in active PsA. This open-label, randomized, controlled trial is the first and only H2H study that utilizes ...